New York Life Investment Management LLC grew its position in Baxter International Inc. (NYSE:BAX – Free Report) by 17.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 163,934 shares of the medical instruments supplier’s stock after acquiring an additional 23,926 shares during the quarter. New York Life Investment Management LLC’s holdings in Baxter International were worth $3,934,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in Baxter International in the 2nd quarter valued at $1,744,874,000. Pzena Investment Management LLC acquired a new stake in shares of Baxter International in the 2nd quarter worth $1,392,098,000. Equity Investment Corp acquired a new stake in shares of Baxter International in the 2nd quarter worth $146,815,000. Bank of America Corp DE acquired a new stake in shares of Baxter International in the 2nd quarter worth $132,993,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Baxter International in the second quarter valued at about $68,036,000. 90.19% of the stock is owned by institutional investors and hedge funds.
Baxter International Trading Down 0.2%
Shares of Baxter International stock opened at $25.77 on Monday. The company has a 50-day moving average of $24.54 and a two-hundred day moving average of $21.67. Baxter International Inc. has a 12-month low of $15.73 and a 12-month high of $30.00. The company has a current ratio of 1.79, a quick ratio of 1.19 and a debt-to-equity ratio of 1.20. The stock has a market cap of $13.33 billion, a PE ratio of -18.28, a price-to-earnings-growth ratio of 3.79 and a beta of 0.68.
Baxter International (NYSE:BAX – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 EPS for the quarter, topping the consensus estimate of $0.52 by $0.06. The business had revenue of $2.98 billion for the quarter, compared to analyst estimates of $2.91 billion. Baxter International had a positive return on equity of 16.23% and a negative net margin of 6.23%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.69 EPS. On average, research analysts anticipate that Baxter International Inc. will post 2.10 EPS for the current fiscal year.
Baxter International Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Friday, November 27th will be paid a dividend of $0.01 per share. The ex-dividend date of this dividend is Friday, November 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. Baxter International’s dividend payout ratio is presently -2.84%.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on BAX shares. Wells Fargo & Company boosted their price target on shares of Baxter International from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Friday, October 30th. UBS Group raised their price objective on shares of Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings raised Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 30th. TD Cowen boosted their target price on Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research report on Monday, July 27th. Finally, Zacks Research raised Baxter International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Baxter International presently has an average rating of “Reduce” and an average price target of $23.27.
Get Our Latest Stock Analysis on Baxter International
Baxter International Company Profile
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
Read More
- Five stocks we like better than Baxter International
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX – Free Report).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
